# Safety and Efficacy of PMT Therapy of hPAP

> **NCT05761899** · PHASE1,PHASE2 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 3 (estimated)

## Conditions studied

- Hereditary Pulmonary Alveolar Proteinosis

## Interventions

- **COMBINATION_PRODUCT:** Gene-Corrected Macrophages administered by bronchoscopic instillation

## Key facts

- **NCT ID:** NCT05761899
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-26
- **Primary completion:** 2026-09-01
- **Final completion:** 2038-10-01
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2025-12-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05761899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05761899, "Safety and Efficacy of PMT Therapy of hPAP". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05761899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*